Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/237949 
Erscheinungsjahr: 
2020
Schriftenreihe/Nr.: 
ESRI Working Paper No. 678
Verlag: 
The Economic and Social Research Institute (ESRI), Dublin
Zusammenfassung: 
Do firms increase product lines to deter entry and, if so, when is such a strategy successful? We use data from UK pharmaceuticals to examine how incumbents respond to change in the threat of entry. In line with the entry deterrence motive, originators' product launch rate is higher when the risk of entry is moderate, but becomes lower when entry is very likely, and the effect is most pronounced in medium-size markets. We further find that in medium-size markets, originators can deny entry via proliferation if they fill the product space evenly across patients so that each variant has a significant market share of the originators drugs. This does not work in large markets, but here entry is deterred when originators engage in product hopping, i.e., shift most of the patients to newer variants of the drug that may still be protected by intellectual property.
Schlagwörter: 
Product proliferation
product hopping
entry deterrence
pharmaceuticals
hazard models
JEL: 
L40
L12
I11
L79
Dokumentart: 
Working Paper

Datei(en):
Datei
Größe
1.35 MB





Publikationen in EconStor sind urheberrechtlich geschützt.